<DOC>
	<DOCNO>NCT01057433</DOCNO>
	<brief_summary>This Phase 4 , single center , open label , fixed-sequence , 2-way drug-drug interaction study .</brief_summary>
	<brief_title>Drug-Drug Interaction Lopinavir/Ritonavir Pitavastatin</brief_title>
	<detailed_description>This Phase 4 , single center , open label , fixed-sequence , 2-way drug-drug interaction study . Each subject qualify entry study 30 day prior admission clinical unit . Subjects check clinical unit Day -1 baseline assessment . There one treatment period , subject receive daily dose pitavastatin 4 mg Days 1 5 Days 20 24 twice daily dose lopinavir/ritonavir 400 mg/100 mg ( two 200 mg/50 mg tablet per dose ) Days 9 24 . Pitavastatin administer fasting condition morning lopinavir/ritonavir administer fasting condition morning evening .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<criteria>Healthy adult male female volunteer age 18 45 year , inclusive . Subject body mass index 18 30 kg/m2 , inclusive . Subject normal hematology , serum chemistry , urinalysis test result Subject able willing abstain alcohol , grapefruit , caffeine , caffeine containing product 4 day Day 1 completion study . Subject nonsmoker quit smoke least 6 month first dose study drug . Subject surgery gastrointestinal tract likely affect drug absorption , distribution , metabolism , excretion . Subject previous allergy intolerance treatment pitavastatin lopinavir/ritonavir . Subject history drug alcohol abuse . Subject clinically significant illness within 4 week first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>